Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCLA-129 + chemotherapy
- Development stage
- Unknown
- Lead developer
- Merus
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
MCLA-129 + chemotherapy is a combination regimen consisting of **MCLA-129**, a bispecific monoclonal antibody targeting both Epidermal Growth Factor Receptor (**EGFR**) and hepatocyte growth factor receptor (**c-MET**), together with cytotoxic chemotherapy agents (not specified, generally platinum-based chemotherapy in non-small cell lung cancer contexts). MCLA-129 is engineered for enhanced antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, and works by inhibiting ligand-dependent phosphorylation of EGFR and c-MET as well as overcoming resistance to tyrosine kinase inhibitors. The combination aims to increase antitumor activity in patients with advanced or metastatic solid tumors, such as non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation (METex14), EGFR exon20 insertion (exon20ins), and sensitizing EGFR mutations. In clinical studies, patients previously treated with platinum-based chemotherapy or tyrosine kinase inhibitors were included[1][5].
- Other names
- MCLA129 + chemotherapy
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on MCLA-129 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCLA-129 + chemotherapy.